The characteristics of bladder cancer after radiotherapy for prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1628-1634

  Abern, Michael R ^a   Dude, Annie M ^a   Tsivian, Matvey ^a   Coogan, Christopher L ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neoplasms; Prostatic neoplasms; Radiotherapy; Second primary; Urinary bladder neoplasms

Indexed keywords

ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CARCINOMA IN SITU; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION EXPOSURE; RETROSPECTIVE STUDY; STANDARDIZED INCIDENCE RATIO; TREATMENT OUTCOME;

NEOPLASMS; PROSTATIC NEOPLASMS; RADIOTHERAPY; SECOND PRIMARY; URINARY BLADDER NEOPLASMS;

COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; OUTCOME ASSESSMENT (HEALTH CARE); PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84886294269     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.006     Document Type: Article

References (23)

1. SEER Cancer Statistics Review, 1975-2008 http://seer.cancer.gov/csr/1975_2008/.
2. Nieder A.M., Porter M.P., Soloway M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: A population based cohort study. J Urol 2008, 180:2005-2009. Discussion, 2009-10.
3. Bhojani N., Capitanio U., Suardi N., et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: A population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 2010, 76:342-348.
4. Moon K., Stukenborg G.J., Keim J., et al. Cancer incidence after localized therapy for prostate cancer. Cancer 2006, 107:991-998.
5. Neugut A.I., Ahsan H., Robinson E., et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 1997, 79:1600-1604.
6. Abdel-Wahab M., Reis I.M., Hamilton K. Second primary cancer after radiotherapy for prostate cancer-a SEER analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:58-68.
7. Corcoran N.M., Hovens C.M., Hong M.K., et al. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 2012, 109:660-664.
8. Li C.I., Nishi N., McDougall J.A., et al. Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors. Cancer Res 2010, 70:7187-7198.
9. Jaamaa S., Af Hallstrom T.M., Sankila A., et al. DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res 2010, 70:8630-8641.
10. Jayram G., Katz M.H., Steinberg G.D. Radical cystectomy in patients previously treated for localized prostate cancer. Urology 2010, 76:1430-1433.
11. Yee D.S., Shariat S.F., Lowrance W.T., et al. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 2010, 183:1751-1756.
12. Freedland S.J., Kane C.J., Amling C.L., et al. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 2006, 175:1298-1302. Discussion:1302-293.
13. Laskin W.B., Silverman T.A., Enzinger F.M. Postradiation soft tissue sarcomas: an analysis of 53 cases. Cancer 1988, 62:2330-2340.
14. Boorjian S., Cowan J.E., Konety B.R., et al. Bladder cancer incidence and risk factors in men with prostate cancer: Results from cancer of the prostate strategic Urologic research endeavor. J Urol 2007, 177:883-888.
15. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
16. Quek M.L., Stein J.P., Nichols P.W., et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol 2005, 174:103-106.
17. Shariat S.F., Chromecki T.F., Cha E.K., et al. Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol 2012, 187:457-462.
18. Singh A., Kinoshita Y., Rovito P.M., et al. Higher than expected association of clinical prostate and bladder cancers. J Urol 2005, 173:1526-1529.
19. Kim E.D., Ignatoff J.M. Unsuspected bladder carcinoma in patients undergoing radical prostatectomy. J Urol 1994, 152:397-400.
20. Hinnen K.A., Schaapveld M., van Vulpen M., et al. Prostate brachytherapy and second primary cancer risk: A competitive risk analysis. J Clin Oncol 2011, 29:4510-4515.
21. Takam R., Bezak E., Yeoh E.E. Risk of second primary cancer following prostate cancer radiotherapy: DVH analysis using the competitive risk model. Phys Med Biol 2009, 54:611-625.
22. Schneider U., Lomax A., Besserer J., et al. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2007, 68:892-897.
23. Rogers C.G., Palapattu G.S., Shariat S.F., et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006, 175(Suppl):2048-2053.